Prophylactic and therapeutic neutralizing monoclonal antibody treatment prevents lethal yellow fever infection
Authors:
- Lauren N. RustLRLauren N. Rust
- Michael J. RicciardiMRMichael J. Ricciardi
- Savannah S. LutzSLSavannah S. Lutz
- Sofiya YusovaSYSofiya Yusova
- Johan J. LouwJLJohan J. Louw
- Aaron Yrizarry-MedinaAYAaron Yrizarry-Medina
- Sreya BiswasSBSreya Biswas
- Miranda FischerMFMiranda Fischer
- Aaron Barber-AxthelmABAaron Barber-Axthelm
- Gavin ZilverbergGZGavin Zilverberg
- Lauren BaileyLBLauren Bailey
- Tonya SwansonTSTonya Swanson
Open Access
- 15 July 2025
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (16)
Abstract
Yellow fever virus (YFV) infection is fatal in 5%–10% of the 200,000 yearly cases. There is currently no available antiviral treatment. We showed previously that administration of 50 mg/kg of a YFV-specific neutralizing monoclonal antibody (nmAb) at 2 days postinfection (dpi), prior to the onset of severe disease, protected YFV-infected rhesus macaques from death. To further explore the clinical applicability of our nmAb MBL-YFV-01, we treated rhesus macaques with a lower dose (10 mg/kg) of this nmAb prophylactically or therapeutically at 3.5 dpi. We show that a single prophylactic or therapeutic i.v. dose of our nmAb protects rhesus macaques from death following challenge. A comprehensive analysis of 167 inflammatory cytokine and chemokines revealed that protection was associated with significantly reduced expression of 125 of these markers, including type I IFN, IL-6, and CCL2. This study further expands the potential clinical use of our YFV-specific nmAb, which could be used during an outbreak for immediate prophylactic immunity or for patients with measurable serum viremia.Keywords
Funding Information
- NIH (R42 AI155275)
- NIH (P51 OD011092)
This publication has 38 references indexed in Scilit:
- Systems Immunology Approaches to Understanding Immune Responses in Acute Infection of Yellow Fever PatientsJournal of Medical Virology, 2024
- Biomarkers of Hepatic Toxicity: An OverviewCurrent Therapeutic Research, 2024
- Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patientsClinical Immunology, 2023
- Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulinPharmacology & Therapeutics, 2022
- The Impact of Climate Change on Vaccine-Preventable Diseases: Insights From Current Research and New DirectionsCurrent Environmental Health Reports, 2020
- Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysisVaccine, 2020
- Viral receptors for flaviviruses: Not only gatekeepersJournal of Leukocyte Biology, 2019
- Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old FoeTrends in Microbiology, 2018
- Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern DayCurrent Infectious Disease Reports, 2017
- Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999–2005Vaccine, 2007